The study demonstrated a clear overall survival benefit for patients receiving maintenance therapy compared to a placebo.
The (often referred to simply as the IFM-05 study) focused on using lenalidomide as a maintenance treatment. IFM_05-May 2022
Research published around May 2022 explored the impact of "early" vs. "late" discontinuation (stopping before or after 3 years), noting that early stopping is often forced by toxicity rather than choice. The study demonstrated a clear overall survival benefit
To determine if continuous low-dose chemotherapy after a transplant could improve overall survival and keep the disease controlled for longer periods. IFM_05-May 2022